Drug Trial Radar · NCT06290128
A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work
Last checked: Nov 19, 2026Latest source record: Aug 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
109
Actual
Start
Jul 12, 2024
Primary completion
Jun 10, 2026
Study completion Oct 31, 2027
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- Mar 4, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to evaluate efficacy of riliprubart compared to placebo in adult participants with CIDP whose disease is refractory to standard of care. The study duration will be for a maximum of 111 weeks including screening, treatment phases, and follow-up.
Conditions
- Chronic Inflammatory Demyelinating Polyradiculoneuropathy
- Polyneuropathy, Inflammatory Demyelinating, Chronic
Interventions
RiliprubartDrug
Pharmaceutical form: Solution Route of administration: IV Infusion
PlaceboDrug
Pharmaceutical form: Solution Route of administration: IV Infusion
RiliprubartDrug
Pharmaceutical form: Solution Route of administration: SC Injection
PlaceboDrug
Pharmaceutical form: Solution Route of administration: SC Injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of participants experiencing a responseTime frame: Baseline to week 24
- Percentage of participants randomized to riliprubart with lasting responseTime frame: Baseline to week 48
- Percentage of participants randomized to placebo who experience a responseTime frame: Week 24 to week 48
Locations
132 sites in 24 countries. Site status is shown where the registry gives one.
Alabama Neurology Associates- Site Number : 8400019
Homewood, Alabama
USC Norris Comprehensive Cancer Center- Site Number : 8400002
Los Angeles, California
University of California Irvine - Manchester Pavilion- Site Number : 8400007
Orange, California
IMMUNOe International Research Centers - Centennial- Site Number : 8400049
Centennial, Colorado
Yale University School of Medicine- Site Number : 8400018
New Haven, Connecticut
Nova Clinical Research - Bradenton- Site Number : 8400044
Bradenton, Florida
Design Neuroscience Center- Site Number : 8400053
Miami Lakes, Florida
NorthShore University Health System - Glenbrook Hospital- Site Number : 8400024
Glenview, Illinois
University of Kansas Medical Center- Site Number : 8400010
Kansas City, Kansas
NeuroMedical Clinic of Central Louisiana- Site Number : 8400031
Alexandria, Louisiana
Ochsner Medical Center - Jefferson Highway- Site Number : 8400030
New Orleans, Louisiana
Johns Hopkins Hospital- Site Number : 8400015
Baltimore, Maryland
Massachusetts General Hospital- Site Number : 8400009
Boston, Massachusetts
Henry Ford Hospital- Site Number : 8400025
Detroit, Michigan
Michigan State University- Site Number : 8400038
East Lansing, Michigan
Washington University School of Medicine - Siteman Cancer Center- Site Number : 8400037
St Louis, Missouri
Profound Research- Site Number : 8400052
Las Vegas, Nevada
Hospital for Special Surgery - Site Number : 8400041
New York, New York
Columbia University Irving Medical Center- Site Number : 8400003
New York, New York
Raleigh Neurology Associates- Site Number : 8400043
Raleigh, North Carolina
University of Cincinnati Medical Center- Site Number : 8400020
Cincinnati, Ohio
University Hospitals Cleveland Medical Center- Site Number : 8400033
Cleveland, Ohio
Penn State Health Milton South Hershey Medical Center- Site Number : 8400042
Hershey, Pennsylvania
Penn Medicine: University of Pennsylvania Health System- Site Number : 8400022
Philadelphia, Pennsylvania
Austin Neuromuscular Center- Site Number : 8400040
Austin, Texas
UTHealth - The University of Texas Health Sciences Center at Houston- Site Number : 8400050
Houston, Texas
University of Vermont Medical Center- Site Number : 8400012
Burlington, Vermont
University of Virginia- Site Number : 8400023
Charlottesville, Virginia
Investigational Site Number : 0320001
Buenos Aires, Argentina
Investigational Site Number : 0320002
Buenos Aires, Argentina
Investigational Site Number : 0320003
Buenos Aires, Argentina
Investigational Site Number : 0560001
Leuven, Belgium
PSEG Centro de Pesquisa Clínica- Site Number : 0760009
São Paulo, Brazil
Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo- Site Number : 0760017
São Paulo, Brazil
Centro de Diagnostico e Pesquisa da Osteoporose do Espirito Santo- Site Number : 0760012
Vitória, Espírito Santo, Brazil
Hospital Sao Rafael- Site Number : 0760011
Salvador, Estado de Bahia, Brazil
Freire Pesquisa Clínica - Belo Horizonte - Rua Piauí- Site Number : 0760016
Belo Horizonte, Minas Gerais, Brazil
Hospital Moinhos de Vento- Site Number : 0760003
Porto Alegre, Rio Grande do Sul, Brazil
Hospital das Clinicas da Faculdade de Medicina de Ribeirao Preto- Site Number : 0760007
Ribeirão Preto, São Paulo, Brazil
Investigational Site Number : 1000002
Blagoevgrad, Bulgaria
Showing 40 of 132 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.